Entrada Therapeutics, Inc. (TRDA) Financials

TRDA Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 298.9 million 65.5 million
March 31, 2026 335.5 million 64.7 million
Dec. 31, 2025 377.4 million 71.2 million
Sept. 30, 2025 412.9 million 72.2 million

TRDA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -35.7 million 9.9 million
March 31, 2026 -41.7 million 4.7 million
Dec. 31, 2025 -32.0 million 4.4 million
Sept. 30, 2025 -28.1 million 5.1 million

TRDA Net Income

No data available :(

TRDA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 223.0 million - 48.5 million
March 31, 2026 254.9 million - 49.8 million
Dec. 31, 2025 295.7 million - 50.9 million
Sept. 30, 2025 326.8 million - 48.1 million

TRDA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 42.2 million
March 31, 2026 41.8 million
Dec. 31, 2025 41.4 million
Sept. 30, 2025 41.5 million

TRDA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 11000 35.4 million 10.5 million -
March 31, 2026 44000 33.1 million 10.1 million -
Dec. 31, 2025 207000 34.0 million 9.6 million -
Sept. 30, 2025 171000 38.4 million 10.3 million -

TRDA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 898000 -
March 31, 2026 875000 805000
Dec. 31, 2025 1.3 million 886000
Sept. 30, 2025 1.6 million 38.4 million

TRDA Revenue by Segment
Graph available only for paid members. Upgrade to see it.

TRDA

Price: $4.37

52 week price:
4.37
16.45

Earnings Per Share: -4.01 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 22900

Market Capitalization: 201.9 million

Links: